BIODESIX, INC. Restricted Cash
BIODESIX, INC. (BDSX) had Restricted Cash of $100.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-08-05
- 2026-06-30: Restricted Cash $100.00K.
- 2026-03-31: Restricted Cash $100.00K.
- 2025-12-31: Restricted Cash $100.00K.
- 2025-09-30: Restricted Cash $100.00K.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-04 |
| 2025-12-31 | $100.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-03 |
| 2025-06-30 | $100.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $100.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-01 |
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $100.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $100.00K 10-K · filed 2024-03-01 |
| 2022-06-30 | $5.10K 10-Q · filed 2022-08-04 |
| 2021-12-31 | $100.00K 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |